

Appendix II

Currently Pending Claims

15. (Amended) A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one homologous DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, and a DNA sequence encoding a Dengue virus serotype 4 antigen.

16. The recombinant MVA virus according to Claim 15, wherein the recombinant MVA virus comprises a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, and a DNA sequence encoding a Dengue virus serotype 4 antigen.

17. The recombinant MVA virus according to Claim 15, wherein the Dengue virus antigen is selected from the group consisting of preM, E and NS1 antigens.

18. (Amended) The recombinant MVA virus according to Claim 15, wherein the DNA sequences are inserted at the site of one or more naturally occurring deletions within the MVA virus genome.

19. The recombinant MVA virus according to Claim 15, wherein the DNA sequences encoding antigens are under transcriptional control of the vaccinia virus early/late promoter P7.5.

20. A pharmaceutical composition comprising at least one recombinant MVA virus according to Claim 15 and a pharmaceutically acceptable carrier or diluent.

21. A pharmaceutical composition comprising at least one recombinant MVA virus according to Claim 16 and a pharmaceutically acceptable carrier or diluent.

22. A pharmaceutical composition comprising at least one recombinant MVA virus according to Claim 19 and a pharmaceutically acceptable carrier or diluent.

23. A method for mounting an immune response in an animal to Dengue virus infection, the method comprising administering to the animal the pharmaceutical composition of Claim 20.

24. The method according to Claim 23, wherein the animal is a human.

25. A method for mounting an immune response in an animal to Dengue virus infection, the method comprising administering to the animal the pharmaceutical composition of Claim 21.

26. The method according to Claim 25, wherein the animal is a human.

27. (Amended) (Allowed) A composition comprising a first and second component, wherein the first component is a vector comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, or a DNA sequence encoding a Dengue virus serotype 4 antigen and wherein the more than one DNA sequences are under the transcriptional control of a T7 RNA polymerase promoter and the second component is a recombinant Modified Vaccinia Ankara (MVA) virus comprising a DNA sequence encoding T7 RNA polymerase and.

28. (Allowed) The composition of Claim 27, wherein the vector of the first component is a plasmid.

32. (Allowed) A cell containing the composition of claim 27.

33. (Amended) A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 preM antigen, a DNA sequence encoding a Dengue virus serotype 2 preM antigen, a DNA sequence encoding a Dengue virus serotype 3 preM antigen, and a DNA sequence encoding a Dengue virus serotype 4 preM antigen.

34. The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 33 comprising a DNA sequence encoding a Dengue virus serotype 1 preM antigen, a DNA sequence encoding a Dengue virus serotype 2 preM antigen, a DNA sequence encoding a Dengue virus serotype 3 preM antigen, and a DNA sequence encoding a Dengue virus serotype 4 preM antigen.

35. A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 E antigen, a DNA sequence encoding a Dengue virus serotype 2 E antigen, a DNA sequence encoding a Dengue virus serotype 3 E antigen, and a DNA sequence encoding a Dengue virus serotype 4 E antigen.

36. The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 35 comprising a DNA sequence encoding a Dengue virus serotype 1 E antigen, a DNA sequence encoding a Dengue virus serotype 2 E antigen, a DNA sequence encoding a Dengue virus serotype 3 E antigen, and a DNA sequence encoding a Dengue virus serotype 4 E antigen.

37. (Amended) A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 2 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 3 NS-1 antigen, and a DNA sequence encoding a Dengue virus serotype 4 NS-1 antigen.

U.S.S.N.: 09/147,919
Attorney Docket No.: 20239-703
Client Docket No: BN 12 PCT-US

38. (Amended) The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 37 comprising a DNA sequence encoding a Dengue virus serotype 1 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 2 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 3 NS-1 antigen, and a DNA sequence encoding a Dengue virus serotype 4 NS-1 antigen.